Pirtobrutinib (LOXO-305) is an advanced BTK inhibitor that displays high selectivity and operates through a non-covalent mechanism. This compound effectively inhibits various BTK C481 substitution mutations, leading to tumor regression in BTK-dependent lymphoma tumors in mouse xenograft models. Furthermore, Pirtobrutinib exhibits remarkable selectivity for BTK, with more than a 300-fold difference compared to 370 other kinases tested. Notably, at a concentration of 1 µM, Pirtobrutinib demonstrates no significant inhibition of non-kinase off-targets.
Molekulargewicht:
479.43
Reinheit:
99.76%
CAS Nummer:
[2101700-15-4]
Formel:
C22H21F4N5O3
Target-Kategorie:
BTK
T36287
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
